Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Reynes, Jacques; Trinh, Roger; Pulido, Federico; Soto-Malave, Ruth; Gathe, Joseph; Qaqish, Roula; Tian, Min; Fredrick, Linda; Podsadecki, Thomas; Norton, Michael; M. Nilius, Angela

doi:10.1089/aid.2011.0275

Public

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Published in AIDS Research and Human Retroviruses • Jun 25, 2012

Authors:

Jacques Reynes

Roger Trinh

Federico Pulido

Abstract

Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study comparing a regimen of lopinavir/ritonavir (LPV/r) 400/100 mg twice daily in combination with either raltegravir (RAL) 40...

Subject

Raltegravir

Emtricitabine

Lopinavir

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!